| Literature DB >> 35106272 |
Haresh Selvaskandan1, Katherine Hull1, Rachel Gregory1, Daniel Pan1, Thrasos Macriyiannis1, Jenny Briggs1, Catherine Richards1, Catherine Mason1, Jorge Jesus-Silva1, Ricky Bell1.
Abstract
Acute respiratory distress syndrome (ARDS) is a rare and under-reported complication of hypercalcemia, which often presents in conjunction with acute kidney injury (AKI). Unfamiliarity with the condition inevitably leads to management uncertainty, resulting in fatal outcomes. Early identification, however, confers a good prognosis. We report a case of a 40-year-old male who presented with severe hypercalcemia and AKI and rapidly deteriorated due to ARDS, with no evidence of cardiogenic pulmonary edema or fluid overload. Infection screens were negative. He died despite invasive ventilation and continuous venous-venous hemofiltration. His autopsy revealed extensive metastatic pulmonary calcifications and alveolar edema. We found only 10 other cases of hypercalcemia-induced ARDS in the literature, with only 2 patients surviving. We provide the first literature review on the subject to guide the management of this rare but fatal complication, which can be managed with good outcomes if considered early. © Dustri-Verlag Dr. K. Feistle.Entities:
Keywords: acute kidney injury; acute respiratory distress syndrome; extra-corporeal membrane oxygenation support; hypercalcemia; parathyroid adenoma; parathyroidectomy; respiratory failure
Year: 2022 PMID: 35106272 PMCID: PMC8802067 DOI: 10.5414/CNCS110464
Source DB: PubMed Journal: Clin Nephrol Case Stud ISSN: 2196-5293
Figure 1Summary of literature search performed.
Cases identified as true ARDS in the context of hypercalcemia. In all cases, hypercalcemia was originally managed with fluid replacement, and MPC was confirmed on histology if the patient did not survive.
| No. | Age | Sex | Survived | Etiology of hypercalcemia | Comorbidities | Calcium mmol/L | Phosphate mmol/L | Calcium phosphate product | Calcitonin | Bisphosphonates | Other management of hypercalcemia | Intubated | ECMO | Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 46 | F | Yes | Parathyroid adenoma | Schizophrenia | 3.79 | 1.84 | 6.97 | Yes | Yes | RRT | Yes | Yes | 9 |
| 2 | 60 | F | No | Parathyroid adenoma | CKD, HTN | 3.69 | 1.32 | 4.87 | No | No | Prednisolone, mithramycin, RRT | Yes | No | 12 |
| 3 | 36 | M | No | Parathyroid adenoma | – | 5.44 | 1.55 | 8.43 | No | No | Furosemide, phosphate, RRT | Yes | No | 3 |
| 4o | 66 | F | No | Parathyroid adenoma | – | 3.14 | 2.55 | 8.01 | No | No | Furosemide, phosphate | Yes | No | 3 |
| 5o | 62 | M | No | Diffuse B-cell lymphoma | – | 3.64 | 1.16 | 4.22 | Yes | No | Furosemide, phosphate, mithramycin | Yes | No | 13 |
| 6 | 51 | F | No | Myeloma | – | 3.12 | 1.91 | 5.96 | No | No | Plasma exchange, RRT | Yes | No | 13 |
| 7 | 57 | M | No | Myeloma | – | 3.84 | Not reported | – | Yes | No | Steroids | No | No | 14 |
| 8* | 41 | F | No | Parathyroid adenoma | – | 5.77 | 2.07 | 11.94 | No | No | Phosphate | No | No | 15 |
| 9 | 73 | M | No | Parathyroid adenoma | – | 5.19 | Not reported | – | No | No | Furosemide, mithramycin | Yes | No | 16 |
| 10 | 60 | M | Yes | Parathyroid adenoma | HTN | > 5.09 | Not reported | – | No | Yes | RRT | No | No | 10 |
| 11 | 40 | M | No | Parathyroid adenoma | Epilepsy, rheumatoid arthritis | 4.38 | 2.07 | 9.06 | Yes | No | Furosemide, steroids, RRT | Yes | No | Our case |
*All cases included a chest radiograph report which demonstrated bilateral infiltrates of lung fields, except case 8, in which no chest radiograph was reported. oAcute kidney injury was reported in all cases except cases 4 and 5. CKD = chronic kidney disease; ECMO = extra-corporeal mechanical oxygenation; HTN = hypertension; M = male; F = female; RRT = renal replacement therapy.
Figure 2Chest radiograph performed at the time of initial oxygen requirement. Formally reported as showing minimal changes.
Figure 3A: Repeat chest radiograph and B: CT pulmonary angiogram performed after intubation.
Figure 4Post-mortem histopathology: A: parathyroid adenoma; B: metastatic pulmonary calcifications (H & E staining, × 400 magnification).